Search - tctmd.com

Displaying 1 - 20 of 51

Sort: Relevancy | Date

Top Heart Failure News of 2024

News Daily News

Top Heart Failure News of 2024

December 31, 2024

December 2024 Dispatch for the CV Team

News Opinion CV Team Dispatch

December 2024 Dispatch for the CV Team

December 20, 2024

FINEARTS-HF Analysis Supports Finerenone’s Value in HFpEF With Obesity

News Daily News

FINEARTS-HF Analysis Supports Finerenone’s Value in HFpEF With Obesity

December 13, 2024

Rethinking the Evidence for ICDs for HFrEF in Light of Today’s GDMT

News Daily News

Rethinking the Evidence for ICDs for HFrEF in Light of Today’s GDMT

December 05, 2024

November 2024 Dispatch for the CV Team

News Opinion CV Team Dispatch

November 2024 Dispatch for the CV Team

November 26, 2024

FDA Approves First ‘Near-Complete’ Stabilizer to Treat ATTR Cardiomyopathy

News Daily News

FDA Approves First ‘Near-Complete’ Stabilizer to Treat ATTR Cardiomyopathy

November 25, 2024

REALIZE-K: Potassium Binder Boosts MRA Use in Hyperkalemic HFrEF Patients

News Conference News AHA 2024

REALIZE-K: Potassium Binder Boosts MRA Use in Hyperkalemic HFrEF Patients

November 22, 2024

Novel CRISPR-Cas9 Therapy Slows ATTR-CM Progression

News Conference News AHA 2024

Novel CRISPR-Cas9 Therapy Slows ATTR-CM Progression

Yael L. Maxwell

November 20, 2024

Spironolactone No Help for the Heart After Acute MI: CLEAR SYNERGY

News Conference News AHA 2024

Spironolactone No Help for the Heart After Acute MI: CLEAR SYNERGY

November 17, 2024

GDMT Uptake Remains Dismal in HFrEF: What’s the Right Fix?

News Features

GDMT Uptake Remains Dismal in HFrEF: What’s the Right Fix?

November 13, 2024

October 2024 Dispatch for the CV Team

News Opinion CV Team Dispatch

October 2024 Dispatch for the CV Team

October 25, 2024

Biomarker and Echo Data Bolster Vutrisiran’s Promise in ATTR-CM

News Conference News HFSA 2024

Biomarker and Echo Data Bolster Vutrisiran’s Promise in ATTR-CM

October 04, 2024

‘Metabolic Accelerator’ Cuts Weight, Not Muscle in HFpEF: HuMAIN-HF

News Conference News HFSA 2024

‘Metabolic Accelerator’ Cuts Weight, Not Muscle in HFpEF: HuMAIN-HF

Michael O'Riordan

October 03, 2024

‘Global Efficacy’ of Aficamten for Obstructive Disease Shown in SEQUOIA-HCM

News Conference News HFSA 2024

‘Global Efficacy’ of Aficamten for Obstructive Disease Shown in SEQUOIA-HCM

October 02, 2024

FINEARTS-HF: New Analyses Ask, Who Benefits Most From Finerenone?

News Conference News HFSA 2024

FINEARTS-HF: New Analyses Ask, Who Benefits Most From Finerenone?

Michael O'Riordan

October 02, 2024

HFSA Stats 2024 a ‘Call to Action’ Against Rising Tide of HF

News Daily News

HFSA Stats 2024 a ‘Call to Action’ Against Rising Tide of HF

October 01, 2024

Yes, Clinical Inertia IS the Leading Cause of GDMT Underuse in HFrEF

News Daily News

Yes, Clinical Inertia IS the Leading Cause of GDMT Underuse in HFrEF

September 20, 2024

FINEARTS-HF: Benefit of Finerenone Extends to HFmrEF and HFpEF Patients

News Conference News ESC 2024

FINEARTS-HF: Benefit of Finerenone Extends to HFmrEF and HFpEF Patients

Michael O'Riordan

September 01, 2024

Edoxaban-Based Long-Term Antithrombotic Therapy for Atrial Fibrillation and Stable Coronary Disease: The EPIC-CAD Randomized Clinical Trial

Presentation ESC 2024

Edoxaban-Based Long-Term Antithrombotic Therapy for Atrial Fibrillation and Stable Coronary Disease: The EPIC-CAD Randomized Clinical Trial

Presenter: Gi-Byoung Nam

September 01, 2024

Edoxaban Monotherapy Wins for AF and Stable Coronary Disease: EPIC-CAD

News Conference News ESC 2024

Edoxaban Monotherapy Wins for AF and Stable Coronary Disease: EPIC-CAD

September 01, 2024

Country

First Name

Last Name

Email

Profession

Organization

Country

CAPTCHA

This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.